A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy.
about
Overview of Antagonists Used for Determining the Mechanisms of Action Employed by Potential Vasodilators with Their Suggested Signaling PathwaysMetabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular DystrophyTreatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophyCombined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers.Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophyNaproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy.Nitric oxide sustains long-term skeletal muscle regeneration by regulating fate of satellite cells via signaling pathways requiring Vangl2 and cyclic GMP.Nitric Oxide Donor Molsidomine Positively Modulates Myogenic Differentiation of Embryonic Endothelial Progenitors.Requirement of inducible nitric oxide synthase for skeletal muscle regeneration after acute damage.Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy.Cell-matrix interactions in muscle disease.Nitric oxide in myogenesis and therapeutic muscle repair.Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy.Functional muscle ischemia in Duchenne and Becker muscular dystrophy.Fat deposition and accumulation in the damaged and inflamed skeletal muscle: cellular and molecular players.Drug Discovery of Therapies for Duchenne Muscular Dystrophy.Redox Control of Skeletal Muscle Regeneration.A new look at cytoskeletal NOS-1 and β-dystroglycan changes in developing muscle and brain in control and mdx dystrophic mice.Autophagy as a new therapeutic target in Duchenne muscular dystrophyNitric oxide prevents atorvastatin-induced skeletal muscle dysfunction and alterations in mice.Sodium nitrate alleviates functional muscle ischaemia in patients with Becker muscular dystrophy.Required role of apoptotic myogenic precursors and toll-like receptor stimulation for the establishment of autoimmune myositis in experimental murine models.
P2860
Q26752401-9B8C212C-465E-4264-9B04-3DA8AC1A463DQ26772002-FBF5CE73-4931-42D2-8CCD-D8DE4280AC1EQ28484851-53715738-BD10-477B-85D7-2E0B2F382FBFQ33599468-8A7AB36A-7BC7-4E2B-ACCF-25FAFA15D437Q33649312-D87E3DFF-DF77-4EB0-A897-201C0FF00749Q35986842-012C4FDF-DEC0-4C5A-AADD-3BB056EBF49EQ36043923-C986D10F-3B5D-4863-BA86-78685B36041CQ36168025-75905035-9CDF-4557-94CC-64BDF4E256A2Q36593335-C2EDF2A1-D5AC-4AD7-85F2-955E1030E52DQ37604365-333CF5D8-B3F0-4089-9114-69979C08E2B9Q37944530-C7B70700-3F04-4611-8F1C-4A81ECBE5093Q38028378-C614D836-0B67-4EE9-BA28-D6A7D4A04945Q38115148-210C1FB3-998E-41B0-B8C4-48B9105BF1A6Q38175976-CFD5150B-D9C8-4F9D-BFF5-0AC4A8634A39Q38411886-D37C6E0B-7649-4D93-A436-CBF1723E74FCQ38480698-8B98E3ED-5995-42DD-860B-F3EE385B8FEBQ39059046-E689241F-D241-4700-AAFB-D18FB650D606Q39123718-D7D180F2-B7EA-4C20-9034-2923D745003DQ41869455-2CAE57DB-739A-4AEC-9650-C49469ED85C6Q44291723-C57BBC63-543F-4B6E-9760-49F12AC1D89FQ46088505-62A9A349-8C6E-434D-8FB1-C25420B1E800Q52655916-FD548E6D-F943-4565-9833-89FB2F1E032C
P2860
A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A dual acting compound releasi ...... e model of muscular dystrophy.
@ast
A dual acting compound releasi ...... e model of muscular dystrophy.
@en
type
label
A dual acting compound releasi ...... e model of muscular dystrophy.
@ast
A dual acting compound releasi ...... e model of muscular dystrophy.
@en
prefLabel
A dual acting compound releasi ...... e model of muscular dystrophy.
@ast
A dual acting compound releasi ...... e model of muscular dystrophy.
@en
P2093
P2860
P50
P1476
A dual acting compound releasi ...... e model of muscular dystrophy.
@en
P2093
Daniela Miglietta
Dario Cattaneo
Roberta Buono
Viviana Pisa
P2860
P304
P356
10.1016/J.PHRS.2011.05.003
P577
2011-05-12T00:00:00Z